Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease

Stevenson, Dara; Tauber, Joseph; Reis, Brenda L.

doi:10.1016/s0161-6420(00)00035-x

Cited by 378 publications

(257 citation statements)

References 19 publications

Supporting

Mentioning

241

Contrasting

Unclassified

Order By: Relevance

“…[14][15][16] At present, there are no detailed studies employing ocular surface tests such as conjunctival impression and brush cytology (BC), tear evaporation and corneal sensitivity to evaluate the effect of topical Cys on cGVHD related dry eye. We evaluated several parameters such as tear evaporation rate, goblet cell density and MUC5AC mRNA expression, before and after topical Cys use in dry eye patients with cGVHD for the first time.…”

Section: Introductionmentioning

confidence: 99%

Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease

Wang

Ogawa

Doğru

et al. 2007

Bone Marrow Transplant

109

View full text Add to dashboard Cite

We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. Visual analog scale symptom scores, corneal sensitivity, Schirmer I test value, tear film break-up time (TBUT), tear evaporation rate and ocular surface vital staining scores were recorded at baseline and at the end of the following one month. Conjunctival impression and brush cytology were performed before and after the treatment. After topical Cys treatment, significant improvements were found in symptom scores, corneal sensitivity, tear evaporation rate, TBUT, vital staining scores, goblet cells density, conjunctival squamous metaplasia grade, inflammatory cell numbers and the MUC5AC expression. Our study suggests that 0.05% topical Cys may be an effective treatment for dry eye patients with cGVHD. The improvements in the ocular surface and tear functions resulted presumably from the decreased inflammation, increased goblet cell density and MUC5AC mRNA expression.

show abstract

Section: Introductionmentioning

confidence: 99%

Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease

Wang

Ogawa

Doğru

et al. 2007

Bone Marrow Transplant

109

View full text Add to dashboard Cite

show abstract

“…In recent years, it has been used for the treatment of dry-eye symptoms in its advanced stages. [6][7][8][9][10][11] In this pilot study, we combined the use of CsA with artificial tear drops in a group of TO patients with documented dry-eye symptoms and compared its use with artificial tear drops alone, in an attempt to reduce dry-eye symptoms more effectively.…”

Section: Introductionmentioning

confidence: 99%

Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients

Altiparmak

Acar

Ozer

et al. 2009

Eye

View full text Add to dashboard Cite

Purpose To determine the beneficial effect of topically administered Cyclosporine A (CsA) for the dry eye findings of thyroid orbitopathy patients. Patients and methods This prospective pilot study included 73 eyes of 42 patients with thyroid orbitopathy who had documented dry eye findings. Patients were randomly assigned into two groups: in group 1 (48 eyes), patients received topical artificial tear-drop treatment. In group 2 (25 eyes), patients received topical CsA and artificial tear-drop treatment. During a mean follow-up of 6 months, change in Schirmer's test with aneasthesia, tear break-up-time (BUT) and impression cytology results were analyzed and were compared between groups. Results The two groups were age (P ¼ 0.449) and gender (P ¼ 0.942) matched. The Schirmer's test (P ¼ 0.441), tear BUT (P ¼ 0.718) and impression score (P ¼ 0.103) were also similar before the treatment in both groups. In group 1, all three parameters improved significantly with treatment (Po0.001 for all). In group 2, Schirmer's test (P ¼ 0.001) and tear BUT (Po0.001) improved, but the impression score (P ¼ 0.175) did not change significantly after treatment. The percentage of patients with improved tear BUT (P ¼ 0.04) and improved impression score (Po0.001) were higher in group 1. At the end of follow-up, group 1 patients had better Schirmer's test (P ¼ 0.004), tear BUT (P ¼ 0.021) and impression scores (Po0.001), than group 2 patients. Conclusions The combined CsA use with artificial tear drops is not more advantageous than the use of artificial tear drops alone, for the dry eye findings of thyroid orbitopathy patients.

show abstract

“…14 There have been several clinical trials investigating the effect of cyclosporine in dry eye patients. [15][16][17] In one, cyclosporine significantly reduced conjunctival Rose Bengal staining, superficial punctuate staining, and ocular irritation symptoms. Cyclosporine has been shown to decrease activated T cells, 15 pro-inflammatory cytokines, 18,19 and epithelial cell apoptosis, 20 and to increase goblet cell density in dry eye with an inflammatory component.…”

Section: Discussionmentioning

confidence: 97%

Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study

Han

Yoon

Jang

2014

Eye

View full text Add to dashboard Cite

Purpose Long-standing prosthetic eye wearing induces ocular surface inflammation. We investigated the short-term effects of topical cyclosporine A 0.05% (Restasis) in patients with ocular discomfort resulting from long-standing prosthetic eye wearing. Methods This was a prospective, interventional case series. Patients who were unilateral prosthetic eye wearers over a period of 5 years were enrolled at a single institution from March to July 2013. The subjects were instructed to instill topical cyclosporine A 0.05% twice per day. Measurements were made pre-treatment and after 1 and 3 months of treatment. Outcome measures were the ocular symptom score, the lid margin abnormality score, the Schirmer test, and the tear meniscus amount, using Fourier-domain optical coherence tomography. Results In total, 20 consecutive patients (mean age: 60.1 years, 8 males, 12 females) were included. Ocular symptoms were improved after treatment for 1 month in all patients (ocular symptom score pre-treatment 76.83 vs 46.75 after treatment; Po0.001). There was no statistically significant difference in lid margin abnormality score or tear meniscus amount. The Schirmer test results were improved after treatment for 3 months (pre-and after treatment, 6.70 vs 11.40; Po0.001). Conclusions Topical cyclosporine A 0.05% showed a satisfactory effect in long-standing prosthetic eye wearers. Ocular symptoms were markedly relieved in all subjects after treatment for 1 month.

show abstract

Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease

Cited by 378 publications

References 19 publications

Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease

Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease

Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients

Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study

Contact Info

Product

Resources

About